Definium Therapeutics
Definium Therapeutics is seeking a Director, Field Operations to build and lead operational capabilities for its anticipated commercial launch. This hands-on leader will translate commercial strategy into reliable field processes, technology, governance, and execution across customer-facing commercial teams. The role involves managing day-to-day field operations infrastructure, partnering with cross-functional teams, and scaling processes from pre-launch through commercialization.
Headquarters
New York, New York, United States
Company Size
1-10 employees
Founded
2019
Definium Therapeutics (formerly MindMed) is a clinical-stage biopharmaceutical company harnessing the therapeutic potential of psychedelic medicine to develop treatments for psychiatric conditions including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. Its lead programs include DT120 ODT, a proprietary formulation of lysergide (LSD) D-tartrate, and DT402, the R-enantiomer of MDMA targeting core symptoms of autism spectrum disorder. The company is guided by precision science and evidence-based development to redefine mental healthcare.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Definium Therapeutics.
Senior Director, Field Deployment and Incentives
Sanofi
Executive Director, Field Operations Strategy & Excellence
Travere Therapeutics
Associate Director, Commercial Operations
Zydus Therapeutics
Director, SalesIQ Field Intelligence
Axtria, Inc.
Director of Sales Effectiveness & Operations
Amylyx Pharmaceuticals
Senior Manager, Field Operations
Ferring